Listed by the USPTO as SCHMIDT, IZABELA MARIA
Tech Center 1600 • Art Units: 1621 1624
This examiner grants 66% of resolved cases
SCHMIDT, IZABELA MARIA has 102 resolved cases and an allowance rate of 65.7%. The median time to allowance is 1212 days. Interviews correspond to a 42.7% lift in the allowance rate, making direct examiner engagement a meaningful option when claim issues require clarification. The relatively limited resolved-case volume means counsel should combine this profile with close review of the application’s specific technology and prosecution history.
The listed companies are Novartis AG, Howard Hughes Medical Institute, and New York University. The listed firms are SEED INTELLECTUAL PROPERTY LAW GROUP LLP, Apex Attorneys at Law, LLP, and DENTONS DAVIS BROWN PC. These organizations identify the research, corporate, and counsel settings represented in the available record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17925776 | BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES | Non-Final OA | University of Florida Research Foundation, Inc. |
| 17766149 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18893747 | FLUORINATED FLUOROPHORES | Non-Final OA | HOWARD HUGHES MEDICAL INSTITUTE |
| 17789047 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | Final Rejection | New York University |
| 18627081 | NOVEL KAPPA OPIOID LIGANDS | Non-Final OA | The Scripps Research Institute |
| 19034034 | Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders | Non-Final OA | Miralogx LLC |
| 18585551 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | Non-Final OA | The University of Toledo |
| 18850362 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION | Non-Final OA | GH RESEARCH IRELAND LIMITED |
| 18896502 | COMPOSITION FOR LOCALIZED FAT REDUCTION WITHOUT PAIN, EDEMA AND SIDE EFFECTS AND METHOD OF ADMINISTRATION THEREOF | Non-Final OA | AMI PHARM CO., LTD. |
| 18265156 | Octahydroisoquinolinyl Derivatives | Non-Final OA | UCB Biopharma SRL |
| 18709949 | Cannabinoid Receptor Modulating Compounds | Non-Final OA | THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human |
| 18834562 | METHOD OF ADMINISTRATION OF BRYOSTATIN FOR THE INDUCTION OF TUMOR ASSOCIATED ANTIGENS | Non-Final OA | BryoLogyx Inc. |
| 18730175 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | Non-Final OA | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. |
| 18036673 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF IN NEURODEGENERATIVE DISEASES | Final Rejection | ARTIVILA BIOPHARMA |
| 18706816 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | Non-Final OA | Allianthera Boston Inc. |
| 18607196 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | Non-Final OA | ESCIENT PHARMACEUTICALS, INC. |
| 18294513 | LPAR1 ANTAGONISTS AND USES THEREOF | Non-Final OA | Contineum Therapeutics, Inc. |
| 18578252 | A SELF-EMULSIFYING DRUG DELIVERY FORMULATION WITH IMPROVED ORAL BIOAVAILABILITY OF LIPOPHILIC COMPOUND | Final Rejection | Avantsar Sdn Bhd |
| 18578240 | Heterocyclic Compounds and Uses Thereof | Non-Final OA | Hangzhou ACEA Pharmaceutical Research Co., Ltd. |
| 17794729 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Non-Final OA | PX ING, LLC |
| 18382636 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | Non-Final OA | MIRUM PHARMACEUTICALS, INC. |
| 18473282 | ERBB/BTK INHIBITORS | Non-Final OA | Dizal Pharmaceutical Co., Ltd. |
| 18258620 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | Non-Final OA | NORTHSEA THERAPEUTICS B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy65.7% of resolved applications examined by Izabela Maria Schmidt were allowed (102 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +42.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Izabela Maria Schmidt took 1,212 days on average from filing to allowance.
Izabela Maria Schmidt examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
